One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1093/annonc/mdz422.002
Copy DOI
Export
Save
Share
Cite Journal: Annals of Oncology |  Publication Date: Nov 1, 2019 |
 Citations: 5 |  License type: publisher-specific-oa |
Affiliation: University of Ulsan, Asan Medical Center, Ulsan College, National Cancer Center Hospital East, Nanjing Medical University, Presbyterian Hospital, New York Hospital Queens, NewYork–Presbyterian Hospital, Cornell University, Institute of Cancer Research of Montpellier, Henan Cancer Hospital, Nanjing Brain Hospital, Aichi Cancer Center, Jilin Province Tumor Hospital, Shanghai Chest Hospital, Tongji Hospital, MSD (United States), Peking University Cancer Hospital
124O - KEYNOTE-181: Pembrolizumab vs chemotherapy in patients (pts) with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line (2L) therapy
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
